{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007260","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.697559+00:00","generated_at":"2026-06-22T01:04:36.138109+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arbutus reports Q3 net loss $17.6M, discontinues AB-836 capsid inhibitor, cash runway into Q2 2024","bullets":["Net loss $17.6M ($0.12/share) vs $24.2M loss Q3 2021; revenue $6.0M (+$2.7M YoY) on Qilu license income.","Cash, equivalents and investments $190.2M; 2022 net cash burn forecast $90-95M; runway into Q2 2024.","Discontinued AB-836 (oral capsid inhibitor) due to ALT elevations in healthy volunteer arm of Phase 1 trial.","AB-729 off-treatment data: HBsAg and HBV DNA suppressed up to 44 weeks post-therapy; no relapses in 9/9 patients.","On-track to complete IND-enabling studies for AB-161 and AB-101, and nominate pan-coronavirus Mpro candidate by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007260","json":"https://secwatch.observer/filing/0001171843-22-007260.json","markdown":"https://secwatch.observer/filing/0001171843-22-007260.md","text":"https://secwatch.observer/filing/0001171843-22-007260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/0001171843-22-007260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/f8k_110922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:04:36.138109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3650760b9acfc9287ad13659705c3dc00cbe8e7","claim":"Arbutus Biopharma Corp reported third quarter ended September 30, 2022 results: revenue $6.0 million, net income $17.6 million, EPS $0.12 per basic and diluted common share.","evidence_excerpt":"the $55 million of proceeds received from Qilu, and believes its cash runway will be sufficient to fund operations into the second quarter of 2024. Revenue Total revenue was $6.0 million for the three months ended September 30, 2022 compared to $3.3 million for the same period in 2021. The increase of $2.7 million was due primarily to $2.3 million of revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184322007260/0001171843-22-007260-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$6.0 million"},{"label":"Net income","value":"$17.6 million"},{"label":"EPS","value":"$0.12 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}